Biomx INC 8-K filings

BiomX Inc. has entered into a Share Purchase and Option Agreement to acquire a 10% stake in M.E.A. Testing Systems Ltd., a developer of electric motor testing systems for drones, with an option for a controlling interest.

BiomX Inc. has amended a promissory note with Water IO Ltd., extending the maturity date and issuing restricted stock as consideration for accrued interest and payment delay.

BiomX Inc. has cancelled 1,013,637 restricted shares to regain compliance with NYSE American listing rules pending shareholder approval of a prior acquisition.

BiomX Inc. has dismissed Kesselman & Kesselman (PwC) as its independent auditor and engaged Barzily & Co. for the fiscal year ending December 31, 2026.

BiomX Inc. shareholders elected a director and approved an increase in shares for the 2026 Equity Incentive Plan.

BiomX Inc. announced an updated informational presentation detailing its strategic transition to a defense and security technology holding company, focusing on threat identification, analysis, and response.

BiomX Inc. has received approval from the NYSE American for a compliance plan to address stockholders' equity deficiencies, extending its listing deadline to September 25, 2027.

BiomX Inc. filed an amendment to its 8-K reports to provide audited financial statements and pro forma data for its recent acquisitions of Zorronet Ltd. and Dr. Frucht Systems Ltd.

BiomX Inc. has established a $2 million convertible credit line with Mandragola Ltd. and issued 2 million common stock warrants.

BiomX Inc. has appointed Roy Rousso as Chief Business Officer, effective July 1, 2026, under a part-time consulting arrangement.

BiomX Inc. announces a significant strategic transformation, discontinuing its legacy phage therapy programs and acquiring controlling interests in defense technology companies DFSL and Zorronet.

BiomX subsidiary Zorronet has signed a framework supply agreement with Israel Railways following a successful 98% success rate pilot program.

BiomX Inc. has acquired a controlling interest in DFSL, an Israeli defense company specializing in LADAR-based detection systems, to bolster its AI-enabled security capabilities.

BiomX Inc. announced that its stockholders overwhelmingly approved the 2026 Equity Incentive Plan at a special meeting held on April 10, 2026.

BiomX Inc. has completed the acquisition of ZorroNet, an Israeli AI defense technology company, for a combination of stock and a promissory note, establishing BiomX as an AI-powered defense technology platform.

BiomX Inc. has entered into an Option Agreement to acquire DR. Frucht Systems Ltd. (DFSL), a developer of LADAR-based anti-drone technology, for a mix of cash, convertible notes, preferred stock, and warrants.

BiomX Inc. received a notice from NYSE American regarding non-compliance with continued listing standards due to insufficient stockholders' equity and a going concern qualification.

BiomX Inc. announced an amendment to its warrants, significantly shortening their term and reducing the exercise price, alongside a strategic pivot towards defense-related applications and a focus on financial discipline.

BiomX Inc. announced significant leadership changes, including the appointment of Michael Oster as CEO and Amir Shalom as a new director, following the resignations of Jonathan Solomon and Dr. Russell Greig.

BiomX Inc. announced the resignation of Alan Moses from its Board of Directors and the appointment of Guy Arieli and Shaked Ran as new independent directors.

BiomX Inc. announced the resignations of two directors and the appointment of Liat Bidas to its Board of Directors.

BiomX Inc. deconsolidates its wholly-owned Israeli subsidiary, BiomX Ltd., following the commencement of insolvency proceedings and the termination of key officers.

BiomX Inc. announced the consummation of a previously disclosed private placement, the appointment of Reuven Yeganeh to its Board of Directors, and the filing of a Certificate of Designations for Series Y Convertible Preferred Stock.

BiomX Inc. announced the termination of a material lease agreement for its subsidiary Adaptive Phage Therapeutics, settling all outstanding obligations with a one-time payment and a letter of credit draw.

BiomX Inc. announced a $3 million private placement of Series Y Convertible Preferred Stock and warrants, granting the investor a board seat and future participation rights.

BiomX Inc.'s Israeli subsidiary, BiomX Ltd., has filed for insolvency following the discontinuation of its Phase 2b study due to resource limitations.

BiomX Inc. announced the discontinuation of its Phase 2b clinical trial for BX004 in Cystic Fibrosis due to resource constraints, leading to significant workforce reductions and a strategic shift.

BiomX Inc. provided an update on its Phase 2b Cystic Fibrosis study, noting an ongoing FDA clinical hold due to a third-party nebulizer and a Data Monitoring Committee recommendation for an adjusted dosing regimen, pushing topline results to Q2 2026.

BiomX Inc. will implement a one-for-nineteen reverse stock split of its common stock, effective November 25, 2025, to boost its per-share price.

BiomX announced its third quarter 2025 financial results, highlighted by positive FDA feedback for BX011 and anticipated feedback on the BX004 clinical hold.